2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. CFTR

CFTR

Cystic fibrosis transmembrane conductance regulator

CFTR

Related Products

PDF 0.68 MB

CFTR (Cystic fibrosis transmembrane conductance regulator), mutations of which cause cystic fibrosis, belongs to the ATP-binding cassette (ABC) transporter family and works as a channel for small anions, such as chloride and bicarbonate. CFTR is composed of two homologous halves, each comprising a transmembrane (TMD) and a nucleotide binding domain (NBD). CFTR activity is regulated by phosphorylation of its cytosolic regulatory (R) domain, and ATP binding and hydrolysis at two NBDs.

CFTR is expressed in many cell types throughout the body, but in the airways it is found mainly in secretory serous cells of the submucosal glands. Transitions between open and closed states of CFTR are regulated by ATP binding and hydrolysis on the cytosolic nucleotide binding domains, which are coupled with the transmembrane (TM) domains forming the pathway for anion permeation. CFTR function is normally tightly controlled as dysregulation can lead to life-threatening diseases such as secretory diarrhoea and cystic fibrosis.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-112267A
    (R)-Olacaftor
    		Modulator 98.07%
    (R)-Olacaftor ((R)-VX-440) is a Cystic fibrosis transmembrane conductance regulator (CFTR) modulator. (R)-Olacaftor has good potential for the study of cystic fibrosis (CF).
    (R)-Olacaftor
  • HY-106203B
    (R)-Crinecerfont
    		Antagonist
    (R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (R)-Crinecerfont
  • HY-147315
    CFTR corrector 9
    		Modulator 98.84%
    CFTR corrector 9 (compound 42) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. CFTR corrector 9 can be used for researching cystic fibrosis (CF) and other CFTR associated disorders.
    CFTR corrector 9
  • HY-153133
    CFTR corrector 11
    		Modulator 99.80%
    CFTR corrector 11 (compound 133) is a CFTR corrector.
    CFTR corrector 11
  • HY-109187B
    (R)-Posenacaftor sodium
    		Inhibitor 98.96%
    (R)-Posenacaftor (R)-PTI-801) sodium is the R enantiomer of Posenacaftor. Posenacaftor is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF).
    (R)-Posenacaftor sodium
  • HY-P1108
    Astressin 2B
    		Antagonist
    Astressin 2B is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC50 values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B antagonizes CRF2-mediated inhibition of gastric emptying.
    Astressin 2B
  • HY-117187
    Corr4A
    		Modulator
    Corr4A is a chemical corrector, which can be used for cystic fibrosis. Corr4A interacts directly with the cystic fibrosis transmembrane conductance regulator (CFTR) or affects indirectly its folding process. Corr4A increases the expression of CFTR ΔF508 on the cell surface, thereby improving its transport to the plasma membrane and increasing the stability of the rescued mutant protein.
    Corr4A
  • HY-116806
    AF-2785
    		Inhibitor
    AF-2785 is a potent CFTR blocker. AF-2785 inhibits the cAMP-activated chloride current in rat epididymal cells with an IC50 of 170.6 μM. AF-2785 can be used in research related to contraceptives.
    AF-2785
  • HY-P3597
    Urocortin III (mouse) (free acid)
    		Agonist
    Urocortin III (mouse) (free acid) is a selective CRF2 receptor agonist (with high affinity for the CRF2 receptor). Urocortin III (mouse) (free acid) significantly inhibits gastric emptying without modifying colonic transit.
    Urocortin III (mouse) (free acid)
  • HY-148806
    Zatonacaftor
    		Modulator
    Zatonacaftor is a modulator of cystic fibrosis transmembrane regulator (CFTR) protein. Zatonacaftor can be used for research of cystic fibrosis.
    Zatonacaftor
  • HY-P10806
    kCAL01
    		Inhibitor
    kCAL01 is a CAL inhibitor with a Ki value of 2.3 μM. kCAL01 is promising for research of cystic fibrosis (CF).
    kCAL01
  • HY-15206A
    Glibenclamide potassium
    		Inhibitor
    Glibenclamide (Glyburide) potassium is a potassium salt of Glibenclamide (HY-15206). Glibenclamid potassium exists in anhydrous and hydrate forms, with higher solubility compared to pure Glibenclamide.
    Glibenclamide potassium
  • HY-126394B
    Bamocaftor potassium
    		Modulator
    Bamocaftor potassium is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor potassium can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research.
    Bamocaftor potassium
  • HY-15206S2
    Glibenclamide-13C6
    		Inhibitor
    Glibenclamide-13C6 (Glyburide-13C6) is 13C labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR). Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. Glibenclamide can induce autophagy.
    Glibenclamide-<sup>13</sup>C<sub>6</sub>
  • HY-W984122
    CFTR corrector 17
    		Modulator 98.05%
    CFTR corrector 17 (example 17) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. CFTR corrector 17 can be used for the study of CFTR-mediated diseases.
    CFTR corrector 17
  • HY-145603S
    Vanzacaftor-d4
    Vanzacaftor-d4 (VX-121-d4) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases.
    Vanzacaftor-d<sub>4</sub>
  • HY-B0679R
    Lubiprostone (Standard)
    		Activator
    Lubiprostone (Standard) is the analytical standard of Lubiprostone. This product is intended for research and analytical applications. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research.
    Lubiprostone (Standard)
  • HY-169536
    CFTR activator 2
    		Activator 99.54%
    CFTR activator 2 (WAY-326769) is an activator of mutant cystic fibrosis transmembrane conductance regulator (mutant-CFTR).
    CFTR activator 2
  • HY-134385
    6-PhEt-dATP
    6-PhEt-dATP is an ATP analog that specifically enhances the function of certain CFTR mutants and is useful for studying cystic fibrosis.
    6-PhEt-dATP
  • HY-13017S4
    Ivacaftor-13C6
    		Agonist
    Ivacaftor-13C6 (VX-770-13C6) is 13C labeled Ivacaftor. Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively.
    Ivacaftor-<sup>13</sup>C<sub>6</sub>
Cat. No. Product Name / Synonyms Application Reactivity